SBB Certification Exam Prep 2026 Updated Practice
Questions, Comprehensive Blood Banking and Transfusion
Review, Detailed Explanations, Verified Answers, Complete
Success Workbook
SECTION 1: BLOOD PRODUCTS (Questions 1-15)
Question 1: A whole blood donor is deferred based on the results of a viral marker
screening test. Which of the following is the CORRECT deferral period for a
donor who tests repeatedly reactive for Hepatitis B surface antigen (HBsAg)?
A) Permanent deferral
B) 6 months deferral
C) 12 months deferral
D) 24 months deferral
Answer: A) Permanent deferral
Rationale: A donor who tests repeatedly reactive for HBsAg is permanently
deferred from donating blood. This is because a repeatedly reactive HBsAg
indicates active Hepatitis B virus infection, which is a transmissible disease
through blood transfusion. The donor may only be reinstated if they subsequently
test negative for HBsAg and meet additional criteria as defined by FDA
regulations and AABB standards. Six months (B), 12 months (C), and 24 months
(D) are deferral periods for other conditions but not for HBsAg repeatedly reactive.
Question 2: Which of the following additive solutions allows for a 42-day storage
period for red blood cells?
A) CPDA-1
B) AS-1 (Adsol)
C) CPD
D) ACD
Answer: B) AS-1 (Adsol)
Rationale: AS-1 (Adsol) is an additive solution that allows red blood cells to be
stored for up to 42 days. AS-1 contains adenine, dextrose, and mannitol, which
,support RBC metabolism and viability during extended storage. CPDA-1 (A)
allows 35 days of storage. CPD (C) allows 21 days of storage. ACD (D) allows 21
days of storage. The extended storage period provided by AS-1 and other additive
solutions (AS-3, AS-5) has improved blood inventory management.
Question 3: Platelet concentrates must be stored under which of the following
conditions to maintain optimal function?
A) 1-6°C with continuous gentle agitation
B) 20-24°C with continuous gentle agitation
C) 1-6°C without agitation
D) 20-24°C without agitation
Answer: B) 20-24°C with continuous gentle agitation
Rationale: Platelets must be stored at 20-24°C (room temperature) with
continuous gentle agitation to maintain their function and prevent activation. Room
temperature storage maintains platelet viability and function, while agitation
prevents platelet clumping and maintains oxygen delivery to the platelets. Storage
at 1-6°C (A, C) would cause platelet activation and loss of function. Storage
without agitation (D) would result in platelet clumping.
Question 4: Which of the following components is prepared by the "top-and-
bottom" method using a blood bag system with integrated filters?
A) Platelet-rich plasma (PRP)
B) Buffy coat platelets
C) Cryoprecipitate
D) Fresh frozen plasma
Answer: B) Buffy coat platelets
Rationale: Buffy coat platelets are prepared using the "top-and-bottom" method,
where whole blood is centrifuged and the components are separated using an
automated extractor. The buffy coat layer (containing platelets and white blood
cells) is collected and pooled with other buffy coats to create a platelet concentrate.
PRP (A) is prepared by the platelet-rich plasma method. Cryoprecipitate (C) is
,prepared from fresh frozen plasma. Fresh frozen plasma (D) is prepared by
separating plasma from whole blood.
Question 5: A donor with a history of travel to a malaria-endemic area must be
deferred for:
A) 6 months
B) 12 months
C) 3 months
D) Permanent deferral
Answer: C) 3 months
Rationale: According to FDA guidance and AABB standards, donors who have
traveled to malaria-endemic areas are deferred for 3 months after returning from
the area. This deferral period allows for the detection of malaria parasites that may
have been acquired during travel. Permanent deferral (D) is for donors who have
been diagnosed with malaria. Six months (A) and 12 months (B) were previous
deferral periods but have been updated to 3 months in current guidelines.
Question 6: The primary purpose of leukoreduction of blood components is to:
A) Reduce the risk of bacterial contamination
B) Reduce the risk of febrile non-hemolytic transfusion reactions and HLA
alloimmunization
C) Improve platelet function
D) Extend the storage time of red blood cells
Answer: B) Reduce the risk of febrile non-hemolytic transfusion reactions and
HLA alloimmunization
Rationale: Leukoreduction (removal of white blood cells from blood components)
primarily reduces the risk of febrile non-hemolytic transfusion reactions (caused by
recipient antibodies against donor leukocytes) and HLA alloimmunization (which
can lead to platelet refractoriness). Leukoreduction also reduces the risk of CMV
transmission. It does not primarily reduce bacterial contamination risk (A) — that
requires bacterial detection methods. Platelet function (C) may be improved by
, leukoreduction but is not the primary purpose. Storage time (D) is not affected by
leukoreduction.
Question 7: Which of the following is an acceptable hemoglobin (Hgb) level for a
female autologous donor?
A) 10.0 g/dL
B) 11.0 g/dL
C) 12.5 g/dL
D) 13.5 g/dL
Answer: B) 11.0 g/dL
Rationale: The minimum hemoglobin level for an autologous donor is 11.0 g/dL
for both males and females (compared to 12.5 g/dL for allogeneic female donors
and 13.0 g/dL for allogeneic male donors). Autologous donors have lower
hemoglobin requirements because the blood is intended for their own use. 10.0
g/dL (A) is below the minimum acceptable level. 12.5 g/dL (C) is the requirement
for allogeneic female donors. 13.5 g/dL (D) is above the requirement for allogeneic
donors.
Question 8: A unit of whole blood is collected and processed into components.
Which of the following is the CORRECT sequence for processing?
A) Centrifuge → Separate plasma → Add additive solution → Leukoreduce →
Store
B) Separate plasma → Centrifuge → Add additive solution → Leukoreduce →
Store
C) Leukoreduce → Centrifuge → Separate plasma → Add additive solution →
Store
D) Add additive solution → Centrifuge → Separate plasma → Leukoreduce →
Store
Answer: C) Leukoreduce → Centrifuge → Separate plasma → Add additive
solution → Store
Rationale: The correct sequence for processing whole blood into components is:
1) Leukoreduce the whole blood (using an in-line filter), 2) Centrifuge the
Questions, Comprehensive Blood Banking and Transfusion
Review, Detailed Explanations, Verified Answers, Complete
Success Workbook
SECTION 1: BLOOD PRODUCTS (Questions 1-15)
Question 1: A whole blood donor is deferred based on the results of a viral marker
screening test. Which of the following is the CORRECT deferral period for a
donor who tests repeatedly reactive for Hepatitis B surface antigen (HBsAg)?
A) Permanent deferral
B) 6 months deferral
C) 12 months deferral
D) 24 months deferral
Answer: A) Permanent deferral
Rationale: A donor who tests repeatedly reactive for HBsAg is permanently
deferred from donating blood. This is because a repeatedly reactive HBsAg
indicates active Hepatitis B virus infection, which is a transmissible disease
through blood transfusion. The donor may only be reinstated if they subsequently
test negative for HBsAg and meet additional criteria as defined by FDA
regulations and AABB standards. Six months (B), 12 months (C), and 24 months
(D) are deferral periods for other conditions but not for HBsAg repeatedly reactive.
Question 2: Which of the following additive solutions allows for a 42-day storage
period for red blood cells?
A) CPDA-1
B) AS-1 (Adsol)
C) CPD
D) ACD
Answer: B) AS-1 (Adsol)
Rationale: AS-1 (Adsol) is an additive solution that allows red blood cells to be
stored for up to 42 days. AS-1 contains adenine, dextrose, and mannitol, which
,support RBC metabolism and viability during extended storage. CPDA-1 (A)
allows 35 days of storage. CPD (C) allows 21 days of storage. ACD (D) allows 21
days of storage. The extended storage period provided by AS-1 and other additive
solutions (AS-3, AS-5) has improved blood inventory management.
Question 3: Platelet concentrates must be stored under which of the following
conditions to maintain optimal function?
A) 1-6°C with continuous gentle agitation
B) 20-24°C with continuous gentle agitation
C) 1-6°C without agitation
D) 20-24°C without agitation
Answer: B) 20-24°C with continuous gentle agitation
Rationale: Platelets must be stored at 20-24°C (room temperature) with
continuous gentle agitation to maintain their function and prevent activation. Room
temperature storage maintains platelet viability and function, while agitation
prevents platelet clumping and maintains oxygen delivery to the platelets. Storage
at 1-6°C (A, C) would cause platelet activation and loss of function. Storage
without agitation (D) would result in platelet clumping.
Question 4: Which of the following components is prepared by the "top-and-
bottom" method using a blood bag system with integrated filters?
A) Platelet-rich plasma (PRP)
B) Buffy coat platelets
C) Cryoprecipitate
D) Fresh frozen plasma
Answer: B) Buffy coat platelets
Rationale: Buffy coat platelets are prepared using the "top-and-bottom" method,
where whole blood is centrifuged and the components are separated using an
automated extractor. The buffy coat layer (containing platelets and white blood
cells) is collected and pooled with other buffy coats to create a platelet concentrate.
PRP (A) is prepared by the platelet-rich plasma method. Cryoprecipitate (C) is
,prepared from fresh frozen plasma. Fresh frozen plasma (D) is prepared by
separating plasma from whole blood.
Question 5: A donor with a history of travel to a malaria-endemic area must be
deferred for:
A) 6 months
B) 12 months
C) 3 months
D) Permanent deferral
Answer: C) 3 months
Rationale: According to FDA guidance and AABB standards, donors who have
traveled to malaria-endemic areas are deferred for 3 months after returning from
the area. This deferral period allows for the detection of malaria parasites that may
have been acquired during travel. Permanent deferral (D) is for donors who have
been diagnosed with malaria. Six months (A) and 12 months (B) were previous
deferral periods but have been updated to 3 months in current guidelines.
Question 6: The primary purpose of leukoreduction of blood components is to:
A) Reduce the risk of bacterial contamination
B) Reduce the risk of febrile non-hemolytic transfusion reactions and HLA
alloimmunization
C) Improve platelet function
D) Extend the storage time of red blood cells
Answer: B) Reduce the risk of febrile non-hemolytic transfusion reactions and
HLA alloimmunization
Rationale: Leukoreduction (removal of white blood cells from blood components)
primarily reduces the risk of febrile non-hemolytic transfusion reactions (caused by
recipient antibodies against donor leukocytes) and HLA alloimmunization (which
can lead to platelet refractoriness). Leukoreduction also reduces the risk of CMV
transmission. It does not primarily reduce bacterial contamination risk (A) — that
requires bacterial detection methods. Platelet function (C) may be improved by
, leukoreduction but is not the primary purpose. Storage time (D) is not affected by
leukoreduction.
Question 7: Which of the following is an acceptable hemoglobin (Hgb) level for a
female autologous donor?
A) 10.0 g/dL
B) 11.0 g/dL
C) 12.5 g/dL
D) 13.5 g/dL
Answer: B) 11.0 g/dL
Rationale: The minimum hemoglobin level for an autologous donor is 11.0 g/dL
for both males and females (compared to 12.5 g/dL for allogeneic female donors
and 13.0 g/dL for allogeneic male donors). Autologous donors have lower
hemoglobin requirements because the blood is intended for their own use. 10.0
g/dL (A) is below the minimum acceptable level. 12.5 g/dL (C) is the requirement
for allogeneic female donors. 13.5 g/dL (D) is above the requirement for allogeneic
donors.
Question 8: A unit of whole blood is collected and processed into components.
Which of the following is the CORRECT sequence for processing?
A) Centrifuge → Separate plasma → Add additive solution → Leukoreduce →
Store
B) Separate plasma → Centrifuge → Add additive solution → Leukoreduce →
Store
C) Leukoreduce → Centrifuge → Separate plasma → Add additive solution →
Store
D) Add additive solution → Centrifuge → Separate plasma → Leukoreduce →
Store
Answer: C) Leukoreduce → Centrifuge → Separate plasma → Add additive
solution → Store
Rationale: The correct sequence for processing whole blood into components is:
1) Leukoreduce the whole blood (using an in-line filter), 2) Centrifuge the
